Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients

  • Mohammad I. SalehEmail author
  • Suhad Bani Melhim
  • Hanguin M. Al-Ramadhani
  • Sameh Alzubiedi
Original Research Article


Background and Objectives

Eltrombopag is a thrombopoietic growth factor that is approved for the treatment of thrombocytopenia in chronic hepatitis C virus (HCV) patients. We aimed to describe eltrombopag population pharmacokinetics in hepatitis C patients. Bayesian statistical approach will be applied to screen for patients’ characteristics associated with eltrombopag pharmacokinetic parameters.


A population pharmacokinetic analysis was conducted using WinBUGS version 1.4.3. Data from 483 individuals with chronic HCV infection were analyzed. This analysis is a secondary analysis of two clinical studies (ENABLE1 and ENABLE2) sponsored by GlaxoSmithKline. Several patients’ characteristics were examined as possible covariates of the population pharmacokinetic model. Prior information from previous studies was incorporated in the bayesian model as prior distribution to estimate pharmacokinetic parameters.


A two-compartment pharmacokinetic model with first-order absorption with exponential error model best fit the data. We identified East Asian race and total bilirubin level as predictors of eltrombopag clearance. Typical value for distributional clearance was 0.762 L/h (95% Bayesian credible set, 0.703–0.826), for volume of distribution of the central and peripheral compartments were 12 L (10.9–13.4) and 10.9 L (10.4–11.5), and for absorption lag time was 0.947 h (0.918–0.977). Assuming an average total bilirubin of 21.7 µmol/L, the typical elimination clearance value for an East Asian patient was 0.14 L/h and for other races was 0.20 L/h.


Eltrombopag pharmacokinetic behavior was described using population bayesian approach. This model can be applied to optimize eltrombopag dosing in order to reduce the incidence of thrombocytopenia in HCV-infected patient receiving interferon-based therapy.


Compliance with Ethical Standards


No funding has been received for the conduct of this study and/or preparation of this manuscript.

Conflicts of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Abad S, Vega A, Hernandez E, Merida E, de Sequera P, Albalate M, et al. Universal sustained viral response to the combination of ombitasvir/paritaprevir/ritonavir and dasabuvir with/without ribavirin in patients on hemodialysis infected with hepatitis C virus genotypes 1 and 4. Am J Nephrol. 2017;45(3):267–72. Scholar
  2. 2.
    Center for Disease Control and Prevention. Surveillance for viral hepatitis—United States, 2015. United States: CDC; 2015.Google Scholar
  3. 3.
    Shiffman ML. Chronic hepatitis C virus: advances in treatment, promise for the future. New York: Springer; 2011.Google Scholar
  4. 4.
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67.CrossRefGoogle Scholar
  5. 5.
    Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23(8):1055–65. Scholar
  6. 6.
    Giannini EG, Savarino V. Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye. J Viral Hepat. 2011;18(1):8–10. Scholar
  7. 7.
    Keohane EM, Walenga JM, Smith LJ. Rodak’s hematology: clinical principles and applications. Philadelphia: Elsevier Saunders; 2015.Google Scholar
  8. 8.
    Aspinall R, Pockros P. The management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther. 2004;20(9):917–29.CrossRefGoogle Scholar
  9. 9.
    Bordin G, Ballare M, Zigrossi P, Bertoncelli MC, Paccagnino L, Baroli A, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol. 1995;13(Suppl 13):S39–43.Google Scholar
  10. 10.
    McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Bailliere’s Best Pract Res Clin Gastroenterol. 2000;14(6):1009–31. Scholar
  11. 11.
    Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol. 2001;113(3):590–5.CrossRefGoogle Scholar
  12. 12.
    Skidmore-Roth L. Mosby’s 2014 nursing drug reference. 27th ed. Mosby: Skidmore Nursing Drug Reference; 2014.Google Scholar
  13. 13.
    Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132(1):103–12. Scholar
  14. 14.
    Hodgson BB, Kizior RJ. Saunders nursing drug handbook 2014—E-Book. Amsterdam: Elsevier Health Sciences; 2013.Google Scholar
  15. 15.
    Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs. 2009;69(5):567–76.CrossRefGoogle Scholar
  16. 16.
    Deng Y, Madatian A, Wire MB, Bowen C, Park J, Williams D, et al. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos. 2011. Scholar
  17. 17.
    Lexi-Comp Inc., American Pharmaceutical Association. Drug information handbook. < 1996/97 > -2008/2009: Lexi-Comp’s clinical reference library. North American ed. Hudson, Ohio Washington, DC: Lexi-Comp, American Pharmaceutical Association; 2009. p. 2117.Google Scholar
  18. 18.
    Farrell C, Hayes SC, Wire M, Zhang J. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. Br J Clin Pharmacol. 2014;77(3):532–44.CrossRefGoogle Scholar
  19. 19.
    Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS book: a practical introduction to Bayesian analysis. Boca Raton: CRC Press; 2012.Google Scholar
  20. 20.
    Wu K, Thapar M, Farrell C, Hayes S, Guo H, Hou M, et al. Population pharmacokinetic and pharmacodynamic modeling and effects on platelet counts of different dosages of eltrombopag in chinese patients with chronic primary immune thrombocytopenia. Clin Ther. 2015;37(7):1382–95. Scholar
  21. 21.
    Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51(6):842–56.CrossRefGoogle Scholar
  22. 22.
    Gibiansky E, Mudd Jr P, Kamel Y, Kamel YM, editors. Population pharmacokinetics of eltrombopag in patients with cancer and healthy subjects. AAPS Annual Meeting; 2009.Google Scholar
  23. 23.
    Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B (Stat Methodol). 2002;64(4):583–639.CrossRefGoogle Scholar
  24. 24.
    Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J. 2012;14(1):119–32.CrossRefGoogle Scholar
  25. 25.
    Ette EI, Williams PJ. Pharmacometrics: the science of quantitative pharmacology. New York: Wiley; 2013.Google Scholar
  26. 26.
    Egger M, Smith GD, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ; 2001.CrossRefGoogle Scholar
  27. 27.
    D’Argenio D. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. Berlin: Springer; 2006.Google Scholar
  28. 28.
    Dunson DB. Commentary: practical advantages of Bayesian analysis of epidemiologic data. Am J Epidemiol. 2001;153(12):1222–6.CrossRefGoogle Scholar
  29. 29.
    Saleh MI. A Bayesian approach for population pharmacokinetic modeling of pegylated interferon α-2a in hepatitis C patients. Clin Pharmacokinet. 2017;56(11):1369–79.CrossRefGoogle Scholar
  30. 30.
    Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, et al. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011. Scholar
  31. 31.
    Hayes S, Mudd PN, Ouellet D, Johnson BM, Williams D, Gibiansky E. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Cancer Chemother Pharmacol. 2013;71(6):1507–20.CrossRefGoogle Scholar
  32. 32.
    Zhang J, Thapar M, Farrell C, Wire MB. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection. Pharm Res. 2015;32(6):2015–28.CrossRefGoogle Scholar
  33. 33.
    Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. Boca Raton: Taylor & Francis; 1982.Google Scholar
  34. 34.
    Lee P, Aizawa H, Gan L, Prakash C, Zhong D. Handbook of metabolic pathways of xenobiotics. New York: Wiley; 2014.CrossRefGoogle Scholar
  35. 35.
    Saleh MI, Obeidat AR, Anter HA, Khanfar AA. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clin Exp Pharmacol Physiol. 2015;42(10):1030–5.CrossRefGoogle Scholar
  36. 36.
    Bonate PL. Pharmacokinetic–pharmacodynamic modeling and simulation. Berlin: Springer; 2011.CrossRefGoogle Scholar
  37. 37.
    Bauer LA. Applied clinical pharmacokinetics 3/E. New York: McGraw-Hill Education; 2014.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.School of PharmacyThe University of JordanAmmanJordan

Personalised recommendations